MOBERG DERMA RECEIVES APPROVAL TO INITIATE CLINICAL TRIAL FOR LIMTOP
The German- Federal Institute for Drugs and Medical Devices (BfArM) has granted Moberg Derma approval to initiate a clinical phase I trial for Limtop. Limtop is an innovative formulation of an immunomodulatory compound with potential to treat actinic keratosis, genital warts and basal cell carcinoma. The objective is a product with short treatment duration, an improved safety profile and an efficacy similar to or better than that of competing preparations.”Limtop has the potential to make a real difference for many patients who currently suffer significant side effects, and we are now